MarginsXMarginsX
Home › Markets › Health Care › SLGL

Sol-Gel Technologies Ltd. (SLGL)

SLGL trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$54.96
-0.29% on the day
Market cap
$179.9M
Micro cap
Revenue · 2025
$19.4M
+68.0% on 2024
Net income · 2025
-$6.1M
-31.6% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 20-F (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1684693/000117891326001552/0001178913-26-001552-index.htm. Net income: SEC 20-F (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerSLGL on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryIsrael
IPO year2018
SEC CIK0001684693
SEC industry codePharmaceutical Preparations
Incorporated inIsrael

Financials · 2025

LineValue
Revenue$19.4M
Net income-$6.1M
Operating income-$7.5M
Net margin-31.6%
Operating margin-38.9%
Revenue growth+68.0%
Cash$11.0M
Total assets$29.9M
P/E (computed)Net income was not positive
P/S (computed)9.3×

Warning signs

Cash runway
Cash-flow positive
$11.0M cash at December 31, 2025
Share count, 1 year
0.0%
2024-12-31 to 2025-12-31 · +20.5% over 3 years
Going-concern doubt
Yes
20-F filed March 19, 2026
Insider net buying, 12 months
$11.2M
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"These conditions raise substantial doubt regarding our ability to continue as a going concern within one year after the date of this annual report."
20-F 2026-03-19
Cash and burn$11.0M cash; operating cash flow $81K a quarter.Report 2025-12-31
Shares outstanding2,786,158 (2025-12-31); 27,857,620 a year earlier; 23,129,469 three years earlier. 1y figure adjusted for split (1-for-10 overall); 3y figure adjusted for split (1-for-10 overall); the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures.Cover page 2025-12-31
Reverse splits, 3 years1; latest 1-for-10 on 2025-05-05Source 2025-05-05
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 1 424B5 takedownsLatest 2026-03-24
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorKesselman & Kesselman C.P.A.s, Tel-Aviv, IsraelPCAOB Form AP 2026-03-30
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $11.2M, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Annual results

Fiscal yearRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
FY 2025
2025-12-31
$19.4M-$6.1M$322K$11.0MNo debt tags$19.4M20-F 2026-03-19
FY 2024
2024-12-31
$11.5M-$10.6M-$13.9M$19.5MNo debt tags$11.5M20-F 2026-03-19
FY 2023
2023-12-31
$1.6M-$27.2M-$17.7M$7.5MNo debt tags$1.6M20-F 2026-03-19
FY 2022
2022-12-31
$3.9M-$14.9M-$9.5M$12.4MNo debt tags$3.9M20-F 2025-04-29
FY 2021
2021-12-31
$31.3M$3.2M-$7.7M$20.1MNo debt tags$31.3M20-F 2024-03-13
FY 2020
2020-12-31
$8.8M-$29.3M-$25.2M$7.1MNo debt tags$8.8M20-F 2023-03-10
FY 2019
2019-12-31
$22.9M-$24.6M-$22.5M$9.4MNo debt tags$22.9M20-F/A 2022-04-07
FY 2018
2018-12-31
$129K-$32.2M-$23.5M$5.3MNo debt tags$129K20-F 2021-03-04

From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-03-24
Latest annual report20-F2026-03-19
Latest quarterly / interim6-K2026-11-12

Source: SEC EDGAR submissions feed, 332 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-9.7%
1 month-19.3%
3 months-34.4%
Year to date+30.8%
1 year+54.9%
From 52-week high-43.7%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
WHWKWhitehawk Therapeutics Inc.$3.01-1.63%$177.6M
NATRNature's Sunshine Products Inc.$10.56+1.93%$183.0M
RNACCartesian Therapeutics Inc.$6.08-4.25%$185.5M
KRROKorro Bio Inc.$12.71-6.61%$174.5M
IFRXInflaRx N.V.$1.18+0.85%$173.9M
ANTXAN2 Therapeutics Inc.$4.47-1.76%$169.6M
ORMPOramed Pharmaceuticals Inc.$3.90+5.12%$169.6M
PYXSPyxis Oncology Inc.$1.41-10.76%$168.6M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier